Zykadia

Chemical Nameceritinib
Dosage FormCapsule/Tablet ( oral; 150mg/ 150mg)
Drug ClassKinase inhibitors
SystemRespiratory
CompanyNovartis
Approval Year2014

Indication

  • For the treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zykadia (ceritinib) Prescribing Information2014Novartis Pharmaceuticals Corporation, East Hanover, New Jersey
Document TitleYearSource
Non-Small Cell Lung Cancer, version 5.2017, NCCN Clinical Practice Guidelines in oncology.2017Journal of the National Comprehensive Cancer Network